Document is current
Any future updates will be listed below
-
Authors
Ishiwada, Naruhiko https://orcid.org/0000-0002-7508-1330
Akaishi, Rina
Kobayashi, Yasuhiro https://orcid.org/0000-0003-3587-6611
Togo, Kanae https://orcid.org/0000-0003-3964-4009
Yonemoto, Naohiro https://orcid.org/0000-0003-3637-2095
Matsuo, Moe https://orcid.org/0009-0000-2112-3710
Kaneko, Shinnosuke https://orcid.org/0009-0007-7312-2606
Law, Amy W.
Kamei, Kazumasa https://orcid.org/0000-0001-7220-5142
-
Funding
Funding for this research was provided by:
Pfizer Japan
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 22 May 2024
First Online: 5 June 2024
Declarations
:
: Naruhiko Ishiwada has received funding for research and honoraria for lectures and consultancy from Pfizer Japan Inc. and funding for research from MSD K.K., Sanofi K.K. and Shionogi & Co., Ltd. Rina Akaishi has received honoraria for consultancy from Pfizer Japan Inc. Kanae Togo, Yasuhiro Kobayashi, Naohiro Yonemoto and Kazumasa Kamei are employees of Pfizer Japan Inc. Moe Matsuo and Shinnosuke Kaneko are an employee of Syneos Health Clinical K.K. Amy W. Law is an employee of Pfizer Inc.
: This study does not contain any research activities performed on human participants or animals by any of the authors.
